These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2516312)

  • 21. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of drugs used in fertility regulation.
    Siemens AJ
    Hum Reprod; 1986 Sep; 1(6):405-10. PubMed ID: 3104401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new delivery system for contraceptive steroids.
    Segal S
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1090-2. PubMed ID: 3118719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical jewelry: Earring patch for transdermal delivery of contraceptive hormone.
    Mofidfar M; O'Farrell L; Prausnitz MR
    J Control Release; 2019 May; 301():140-145. PubMed ID: 30876952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations.
    Harrison LI; Zurth C; Gunther C; Karara AH; Melikian A; Lipp R
    Drug Dev Ind Pharm; 2007 Apr; 33(4):373-80. PubMed ID: 17523002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
    Elkik F; Basdevant A; Corvol P
    Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proniosome based transdermal delivery of levonorgestrel for effective contraception.
    Vora B; Khopade AJ; Jain NK
    J Control Release; 1998 Jul; 54(2):149-65. PubMed ID: 9724902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant neoplasms of decidual origin (deciduosarcomas) induced by estrogen-progestin-releasing intravaginal devices in rabbits.
    Zook BC; Spiro I; Hertz R
    Am J Pathol; 1987 Aug; 128(2):315-27. PubMed ID: 3039851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal contraception methods: today's patches and new options on the horizon.
    Nelson AL
    Expert Opin Pharmacother; 2015 Apr; 16(6):863-73. PubMed ID: 25800084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations.
    Funke AP; Schiller R; Motzkus HW; Günther C; Müller RH; Lipp R
    Pharm Res; 2002 May; 19(5):661-8. PubMed ID: 12069170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of vehicles on human skin permeation of norgestrel and levonorgestrel in vitro].
    Zhong JP; Zhou RR; Chen GS; Wang Y; Wang JG
    Yao Xue Xue Bao; 1991; 26(12):933-7. PubMed ID: 1823994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal contraception: new long-acting methods.
    Liskin L; Blackburn R
    Popul Rep K; 1987; (3):K57-87. PubMed ID: 3111901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
    Goldzieher JW
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):318-22. PubMed ID: 2196804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phasic approach to oral contraceptives.
    Hale RW
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1052-8. PubMed ID: 3118718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.